The measured CSF/plasma donepezil concentration ratio but not individually measured CSF and plasma concentrations significantly increase over 24 h after donepezil treatment in patients with Alzheimer's disease
Jazyk angličtina Země Francie Médium print-electronic
Typ dokumentu randomizované kontrolované studie, časopisecké články
PubMed
36630846
DOI
10.1016/j.biopha.2023.114223
PII: S0753-3322(23)00011-2
Knihovny.cz E-zdroje
- Klíčová slova
- AChE-Is, Alzheimer’s disease, CSF, Donepezil, Plasma, Ratio,
- MeSH
- acetylcholinesterasa MeSH
- Alzheimerova nemoc * krev mozkomíšní mok farmakoterapie MeSH
- cholinesterasové inhibitory * krev mozkomíšní mok terapeutické užití MeSH
- donepezil * krev mozkomíšní mok terapeutické užití MeSH
- indany terapeutické užití farmakologie MeSH
- lidé MeSH
- piperidiny farmakologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- acetylcholinesterasa MeSH
- cholinesterasové inhibitory * MeSH
- donepezil * MeSH
- indany MeSH
- piperidiny MeSH
BACKGROUND: The acetylcholinesterase inhibitor donepezil is administered as a treatment for Alzheimer's disease (AD). However, the appropriate donepezil dosage is still a matter of debate. METHODS: Forty AD patients receiving 10 mg/day of donepezil were randomly divided into four groups based on the time of plasma and cerebrospinal fluid (CSF) sampling: 6 h (n = 5), 12 h (n = 12), 18 h (n = 6) and 24 h (n = 17) after donepezil administration. High-performance liquid chromatography measured the donepezil concentration in plasma samples and CSF samples collected at 4-time points. RESULTS: Plasma and CSF levels among the groups were not significantly different. Conversely, the CSF/plasma donepezil concentration ratio considerably increased in the 24 h group compared to the 6 h (p < 0.005) and 12 h (p < 0.05) groups. CONCLUSION: The measurement of the CSF/plasma donepezil concentration ratio could be used to better evaluate the optimal dose of donepezil.
Citace poskytuje Crossref.org
